{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T02:17:16Z","timestamp":1785377836707,"version":"3.55.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2016,10,2]],"date-time":"2016-10-02T00:00:00Z","timestamp":1475366400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2016,10,2]],"date-time":"2016-10-02T00:00:00Z","timestamp":1475366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1111\/bjd.14702","type":"journal-article","created":{"date-parts":[[2016,4,23]],"date-time":"2016-04-23T09:05:29Z","timestamp":1461402329000},"page":"741-751","source":"Crossref","is-referenced-by-count":139,"title":["Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study"],"prefix":"10.1093","volume":"176","author":[{"given":"K.","family":"Yamasaki","sequence":"first","affiliation":[{"name":"Department of Dermatology; Tohoku University Graduate School of Medicine; Tohoku University Hospital; 1-1 Seiryo-cho Aoba-ku Sendai Miyagi 980-8574 Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Dermatology; The Jikei University School of Medicine; Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Kubo","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Institute of Biomedical Sciences; Tokushima University Graduate School; Tokushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Ootaki","sequence":"additional","affiliation":[{"name":"Kyowa Hakko Kirin Co. Ltd; Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Japanese Brodalumab Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,10,2]]},"reference":[{"key":"10.1111\/bjd.14702-BIB0001|bjd14702-cit-0001","first-page":"815","article-title":"Practice guidelines 2010 for generalized pustular psoriasis (GPP): treatment guidelines incorporating TNF-\u03b1 inhibitor","volume":"120","author":"Iwatsuki","year":"2010","journal-title":"Jpn J Dermatol"},{"key":"10.1111\/bjd.14702-BIB0002|bjd14702-cit-0002","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/sj.jid.5701213","article-title":"Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells","volume":"128","author":"Lowes","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.14702-BIB0003|bjd14702-cit-0003","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00403-012-1229-1","article-title":"Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis","volume":"304","author":"Yilmaz","year":"2012","journal-title":"Arch Dermatol Res"},{"key":"10.1111\/bjd.14702-BIB0004|bjd14702-cit-0004","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/jdv.12272","article-title":"Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial","volume":"28","author":"Bissonnette","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.14702-BIB0005|bjd14702-cit-0005","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1684\/ejd.2008.0572","article-title":"Bullous pemphigoid followed by pustular psoriasis showing Th1, Th2, Treg and Th17 immunological changes","volume":"19","author":"Yasukawa","year":"2009","journal-title":"Eur J Dermatol"},{"key":"10.1111\/bjd.14702-BIB0006|bjd14702-cit-0006","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1111\/j.1365-2133.2010.10002.x","article-title":"A case of generalized psoriasiform and pustular eruption induced by infliximab: evidence for skin-homing Th17 in the pathogenesis","volume":"163","author":"Teraki","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.14702-BIB0007|bjd14702-cit-0007","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/jamadermatol.2015.2","article-title":"Immunologic overlap of helper T-cell subtypes 17 and 22 in erythrodermic psoriasis and atopic dermatitis","volume":"151","author":"Moy","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1111\/bjd.14702-BIB0008|bjd14702-cit-0008","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.14702-BIB0009|bjd14702-cit-0009","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.jaad.2014.08.039","article-title":"Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment","volume":"71","author":"Papp","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.14702-BIB0010|bjd14702-cit-0010","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.14702-BIB0011|bjd14702-cit-0011","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1315231","article-title":"Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis","volume":"370","author":"Mease","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.14702-BIB0012|bjd14702-cit-0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdermsci.2014.05.007","article-title":"Clinical pharmacology of the anti-IL-17 receptor antibody brodalumab (KHK4827) in Japanese normal healthy volunteers and Japanese subjects with moderate to severe psoriasis: a randomized, dose-escalation, placebo-controlled study","volume":"75","author":"Osamu","year":"2014","journal-title":"J Dermatol Sci"},{"key":"10.1111\/bjd.14702-BIB0013|bjd14702-cit-0013","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jdermsci.2015.10.009","article-title":"Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study","volume":"81","author":"Nakagawa","year":"2016","journal-title":"J Dermatol Sci"},{"key":"10.1111\/bjd.14702-BIB0014|bjd14702-cit-0014","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/jdv.12773","article-title":"Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis","volume":"29","author":"Saeki","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.14702-BIB0015|bjd14702-cit-0015","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"10.1111\/bjd.14702-BIB0016|bjd14702-cit-0016","first-page":"1583","article-title":"Development of the Japanese version of the Psoriasis Disability Index (PDI), the psoriasis specific QOL index: results of the validation study","volume":"116","author":"Fukuchi","year":"2006","journal-title":"Jpn J Dermatol"},{"key":"10.1111\/bjd.14702-BIB0017|bjd14702-cit-0017","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36)","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"10.1111\/bjd.14702-BIB0018|bjd14702-cit-0018","unstructured":"Iwatsuki K Health, Labour and Welfare Grant-in-Aid for Scientific Research (Intractable Diseases Overcome Research Projects) in 2008 fiscal year to 22 year comprehensive research report Research on rare intractable skin disease [in Japanese] http:\/\/www.nanbyou.or.jp\/english\/nan_kenkyu_45.htm"},{"key":"10.1111\/bjd.14702-BIB0019|bjd14702-cit-0019","unstructured":"Ministry of Health, Labour and Welfare Minister's Secretariat, Statistics and Information Department. 2013 fiscal health administration reported cases [in Japanese] http:\/\/www.nanbyou.or.jp\/english\/nan_kenkyu_45.htm"},{"key":"10.1111\/bjd.14702-BIB0020|bjd14702-cit-0020","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1346-8138.2010.00971.x","article-title":"Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma","volume":"38","author":"Torii","year":"2011","journal-title":"J Dermatol"},{"issue":"Suppl. 2","key":"10.1111\/bjd.14702-BIB0021|bjd14702-cit-0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2009.03389.x","article-title":"European S3-guidelines on the systemic treatment of psoriasis vulgaris","volume":"23","author":"Pathirana","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.14702-BIB0022|bjd14702-cit-0022","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1346-8138.2011.01459.x","article-title":"Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab","volume":"39","author":"Torii","year":"2012","journal-title":"J Dermatol"},{"key":"10.1111\/bjd.14702-BIB0023|bjd14702-cit-0023","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1038\/jid.2013.230","article-title":"The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist","volume":"133","author":"Sugiura","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.14702-BIB0024|bjd14702-cit-0024","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJMoa1013068","article-title":"Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis","volume":"365","author":"Marrakchi","year":"2011","journal-title":"N Engl J Med"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.14702","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.14702","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.14702\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:20:59Z","timestamp":1676384459000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/176\/3\/741\/6840393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,2]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.14702","archive":["Portico"],"relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10,2]]}}}